3 Price Catalysts For Eli Lilly

When I last wrote about the obesity treatments' specialist Eli Lilly (NYSE: LLY ) in August, there was a 50% upside to the stock following its crash after disappointing drug trial results. In the two months since, the stock has realised ~30% of the upside farManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green econ ...